Acorda writes off $363M drug, axing PhIII Parkinson’s drug in the wake of 5 patient deaths
Five days after Acorda said it was suspending enrollment after tracking the deaths of 5 patients from sepsis in a late-stage study of the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
